Cartesian therapeutics announces first patient dosed in first-in-human phase 1 trial of next-generation mrna car-t cell therapy descartes-15

Descartes-15 observed to achieve an approximately ten-fold increase relative to descartes-08 in car expression and selective target-specific killing in preclinical studies
CAR Ratings Summary
CAR Quant Ranking